Biotalys: Biofungicide Evoca Enters Public Consultation in California
Agricultural biotechnology company Biotalys announced on Wednesday that its biofungicide Evoca has entered the public consultation phase with the Californian regulator. This step follows a positive opinion from California's health assessment branch, bringing the candidate closer to approval in the largest agricultural state in the U.S.
Public Consultation Launched After Positive Review
The California Department of Pesticide Regulation (CDPR) initiated the public consultation phase for the Evoca dossier on Wednesday, following a favorable recommendation from its health assessment branch. This branch concluded that the data and information submitted by Biotalys support the registration of the product in California.
The public consultation will last until July 26, allowing stakeholders and the public to comment on the proposed decision. After this period, the CDPR will review the feedback received and is expected to move towards a final regulatory decision in the second half of 2026.
California, a Strategic Market for Biotalys
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
California is the largest agricultural state in the United States, with a production of fruits and vegetables including strawberries, tomatoes, and grapes, making it a strategic market for Biotalys' biocontrol portfolio. This progress comes a few months after the regulatory approval of Evoca in Florida, the first U.S. approval of a biofungicide developed by the company.
Evoca is a protein-based biocontrol intended to combat fungal diseases such as botrytis (gray mold) and powdery mildew. Its approval would pave the way for the regulatory submission of Evoca NG, a next-generation version of the product, with commercial launch planned in the U.S. in 2029 and in Europe in 2030.
Related
SectorProduits Chimiques›Engrais
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 2025
Guidance from the release
En 2025, nous avons atteint un point d'inflexion majeur avec l'approbation de notre premier biocontrole.
Nous renforçons notre concentration sur les programmes de biofongicides les plus avancés.
Risks mentioned
Biotalys n'a pas suffisamment de fonds de roulement pour couvrir ses besoins pendant au moins 12 mois.
La société a seulement une visibilité de trésorerie jusqu'à fin mai 2026.
Opportunities identified
Partenariat stratégique avec AgroFresh pour le marché post-récolte.
Développement de programmes avancés de biofongicides.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
